The Division of Cancer Prevention focuses on the development of novel strategies for the prevention of various human cancers following a multi-disciplinary approach.
Areas of emphasis:
Our Division includes three specialized sections that support its mission:
The Pathology Section is fully equipped to perform routine pathology evaluation of cancer specimens, immunohistochemistry, immunofluorescence, and confocal microscopy. Drs. Nengtai Ouyang (Director) and Yu Sun are fully trained and experienced experimental pathologists. In addition, our Division has full access to the resources of the Department of Pathology at the Stony Brook School of Medicine.
Drug Metabolism Section
The Drug Metabolism Section is staffed by Dr. Gang Xie who has extensive academic and industry experience in the development of novel drugs. This section is equipped with an HPLC system that consists of a Waters Alliance 2695 Separations Module with a Waters 2998 photodiode array detector (260 nm) and a Thermo Hypersil BDS C18 column. A Thermo TSQ Quantum Access (Thermo-Fisher) Triple State Quadrupole Mass Spectrometer system is also available in our Core Facility. In addition, our Division has full access to the resources of the Department of Chemistry at Stony Brook University.
The Nanotechnology Section is staffed by Dr. Georgios Matthaiolampakis, who has extensive experience with the preparation of nano- and micro- sized drug carriers and delivery systems, particle characterization, and analytical and immunotechniques. Additionally, the Division has access to the resources of the Department of Materials Science and Engineering at Stony Brook University.
The Division of Cancer Prevention embodies a structured approach that covers the entire spectrum of research from the earliest basic knowledge all the way to its final translational component. Our work focuses on integrating the use of novel sensors and (micro)imaging modalities for the early detection of cancer based on chemical and other structural changes of the cancer cell; on the delineation of relevant pathways and interactions with novel drugs; and on the validation of preclinical findings through clinical trials conducted in our hospital.